Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

  • ID: 1314904
  • SWOT Analysis
  • 91 pages
  • GlobalData
  • Novartis AG
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Eli Lilly and Co
  • Hoffmann-La Roche Inc
  • Merck & Co Inc
  • Pfizer Inc
  • MORE
Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

Feb 09, 2018: Novartis layoffs to start in April at closing Broomfield plant
Jan 25, 2018: Roche and Novartis accused of anti-competitive conduct by EU court
Jan 24, 2018: Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
Jan 16, 2018: Another Large Pharma Implements Berkeley Lights' Beacon OptoFluidic Platform for Accelerating Antibody Discovery
Jan 11, 2018: Novartis appoints Elizabeth Barrett as Oncology Head

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Eli Lilly and Co
  • Hoffmann-La Roche Inc
  • Merck & Co Inc
  • Pfizer Inc
  • MORE
Section 1 - About the Company
  • Novartis AG - Key Facts
  • Novartis AG - Key Employees
  • Novartis AG - Key Employee Biographies
  • Novartis AG - Major Products and Services
  • Novartis AG - History
  • Novartis AG - Company Statement
  • Novartis AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Novartis AG - Business Description
  • Business Segment: Alcon
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Innovative Medicines (IM)
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Other Revenue
  • Overview
  • Performance
  • Business Segment: Sandoz
  • Overview
  • Performance
  • Key Stats
  • Geographical Segment: Americas (including the US, Canada and Latin America)
  • Performance
  • Geographical Segment: Asia, Africa, Australasia
  • Performance
  • Geographical Segment: Europe (Switzerland, Germany, France, the UK)
  • Performance
  • R&D Overview
  • Novartis AG - Corporate Strategy
  • Novartis AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Novartis AG - Strengths
  • Novartis AG - Weaknesses
  • Novartis AG - Opportunities
  • Novartis AG - Threats
  • Novartis AG - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Novartis AG, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jan 25, 2018: Roche and Novartis accused of anti-competitive conduct by EU court
  • Jan 25, 2018: Roche and Novartis accused of anti-competitive conduct by EU court
  • Jan 25, 2018: Roche and Novartis accused of anti-competitive conduct by EU court
  • Jan 24, 2018: Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
  • Jan 16, 2018: Another Large Pharma Implements Berkeley Lights' Beacon OptoFluidic Platform for Accelerating Antibody Discovery
  • Jan 11, 2018: Novartis appoints Elizabeth Barrett as Oncology Head
  • Dec 15, 2017: Novartis announces Oncology head to retire
  • Nov 28, 2017: Biosimilar drugs have the potential to save more than USD 54 billion
  • Nov 21, 2017: Journal for ImmunoTherapy of Cancer Highlights New Single Cell Bioinformatics Tools From IsoPlexis Used To Characterize Differences in CAR-T Products
  • Nov 16, 2017: Biden Cancer Initiative, Michael J. Fox Foundation for Parkinson's Research, Novartis and Others Support Bridging Clinical Research & Clinical Health Care Collaborative
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Novartis AG, Key Facts
  • Novartis AG, Key Employees
  • Novartis AG, Key Employee Biographies
  • Novartis AG, Major Products and Services
  • Novartis AG, History
  • Novartis AG, Subsidiaries
  • Novartis AG, Key Competitors
  • Novartis AG, Ratios based on current share price
  • Novartis AG, Annual Ratios
  • Novartis AG, Annual Ratios
  • Novartis AG, Annual Ratios
  • Novartis AG, Interim Ratios
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Novartis AG, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Novartis AG, Performance Chart (2013 - 2017)
  • Novartis AG, Ratio Charts
  • Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Sanofi
  • Pfizer Inc
  • Novo Nordisk AS
  • Merck & Co Inc
  • Johnson & Johnson
  • Hoffmann-La Roche Inc
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • AstraZeneca Plc
  • Amgen Inc
  • AbbVie Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll